Table 5 Subsequent therapy use in patients treated to disease progression
Subsequent therapies | Patients treated to PD | |
|---|---|---|
nab-P + Gem (n = 224) | Gem (n = 233) | |
Any subsequent therapy, n (%) | 117 (52) | 133 (57) |
OS, median, months | 11.3 | 9.4 |
HR (95 % CI) | 0.75 (0.57-0.97) | |
P value | 0.027 | |
5-FU/capecitabine based, n (%)a | 99 (85) | 109 (82) |
OS, median, months | 11.6 | 9.2 |
HR (95 % CI) | 0.71 (0.53–0.94) | |
P value | 0.017 | |
FOLFIRINOX (modified/unmodified), n (%)a | 14 (12) | 18 (14) |
OS, median, months | 15.3 | 7.6 |
HR (95 % CI) | 0.45 (0.20–1.00) | |
P value | 0.044 | |
FOLFOX/OFF, n (%)a | 27 (23) | 37 (28) |
OS, median, months | 13.5 | 9.5 |
HR (95 % CI) | 0.58 (0.34–0.98) | |
P value | 0.038 | |
Other, n (%)a | 18 (15) | 24 (18) |
OS, median, months | 10.0 | 10.4 |
HR (95 % CI) | 1.00 (0.53–1.88) | |
P value | >0.999 | |
No subsequent therapy, n (%) | 107 (48) | 100 (43) |
OS, median, months | 7.9 | 5.2 |
HR (95 % CI) | 0.62 (0.46–0.82) | |
P value | <0.001 | |